Kidney drug plan divides transplant and dialysis supporters

The New York Times: "A Congressional proposal to help pay for drugs needed by transplant recipients to prevent rejection of donated kidneys has run into opposition from dialysis providers, drug companies and the National Kidney Foundation." The groups support extending Medicare drug coverage but say the measure would cut funding for dialysis. "The proposal has created a rift between those in the business of providing dialysis and those in the business of performing transplants. The discord is being felt on Capitol Hill, and supporters of the measure fear it may make it easy for Congress to kill the provision altogether in the late stages of negotiation." Meanwhile, the House health overhaul bill "includes a provision that would provide Medicare coverage for immunosuppressant drugs for all beneficiaries for life, starting in 2012." But the issue is currently not addressed in the Senate health bill, though "the second-ranking Democrat in the Senate, Richard J. Durbin of Illinois, last week submitted an amendment that replicates the House language, giving the provision a badly needed lift" (Sack, 12/14).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The global challenge of weight-related issues in kidney disease